Search

Your search keyword '"van Akkooi, A."' showing total 1,516 results
Start Over Author "van Akkooi, A."
1,516 results on '"van Akkooi, A."'

201. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., primary, Bonenkamp, Johannes J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Blokx, Willeke A. M., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfons J. M., additional, Franken, Margreet G., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Westgeest, Hans M., additional, Wouters, Michel W. J. M., additional, and van Akkooi, Alexander C. J., additional

Published
2022
Full Text
View/download PDF

203. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Author

Eggermont, Alexander M.M., primary, Kicinski, Michal, additional, Blank, Christian U., additional, Mandala, Mario, additional, Long, Georgina V., additional, Atkinson, Victoria, additional, Dalle, Stéphane, additional, Haydon, Andrew, additional, Meshcheryakov, Andrey, additional, Khattak, Adnan, additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, Larkin, James, additional, Puig, Susana, additional, Ascierto, Paolo A., additional, Rutkowski, Piotr, additional, Schadendorf, Dirk, additional, Boers-Sonderen, Marye, additional, Di Giacomo, Anna Maria, additional, van den Eertwegh, Alfonsus J.M., additional, Grob, Jean-Jacques, additional, Gutzmer, Ralf, additional, Jamal, Rahima, additional, van Akkooi, Alexander C.J., additional, Lorigan, Paul, additional, Grebennik, Dmitri, additional, Krepler, Clemens, additional, Marreaud, Sandrine, additional, Suciu, Stefan, additional, and Robert, Caroline, additional

Published
2022
Full Text
View/download PDF

204. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., primary, Bonenkamp, Johannes J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Blokx, Willeke A. M., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfons J. M., additional, Franken, Margreet G., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Westgeest, Hans M., additional, Wouters, Michel W. J. M., additional, and van Akkooi, Alexander C. J., additional

Published
2022
Full Text
View/download PDF

205. Postoperative radiotherapy in stage I-III Merkel cell carcinoma

Author

Levy, Sonja, primary, Blankenstein, Stephanie A., additional, Grünhagen, Dirk Jan, additional, Jalving, Mathilde, additional, Hamming-Vrieze, Olga, additional, Been, Lukas B., additional, Tans, Lisa, additional, van Akkooi, Alexander C.J., additional, and Tesselaar, Margot E.T., additional

Published
2022
Full Text
View/download PDF

206. 850P A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Author

Taylor, A.M., primary, Galea, C., additional, Varey, A.H.R., additional, Shannon, K.F., additional, Ch'ng, S., additional, Saw, R.P.M., additional, Pennington, T.E., additional, Stretch, J., additional, Spillane, A.J., additional, van Akkooi, A.C.J., additional, Pires da Silva, I., additional, Carlino, M.S., additional, Scolyer, R.A., additional, Long, G.V., additional, Lo, S.N., additional, and Menzies, A.M., additional

Published
2022
Full Text
View/download PDF

207. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Author

Versluis, J.M., primary, Elens, R., additional, Reijers, I.L.M., additional, Menzies, A.M., additional, Van der Veldt, A.A.M., additional, Kapiteijn, E., additional, Rozeman, E.A., additional, Klop, M.C., additional, Van Houdt, W., additional, Saw, R.P.M., additional, Zuur, C.L., additional, Pennington, T.E., additional, van de Wiel, B., additional, Scolyer, R.A., additional, Broeks, A., additional, van Akkooi, A.C.J., additional, Long, G.V., additional, and Blank, C.U., additional

Published
2022
Full Text
View/download PDF

208. 797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm

Author

Reijers, I.L.M., primary, Menzies, A.M., additional, Versluis, J.M., additional, Dimitriadis, P., additional, Wouters, M., additional, Saw, R.P.M., additional, Klop, M.C., additional, Pennington, T.E., additional, Van Houdt, W., additional, Bosch, L.J.W., additional, Cornelissen, S., additional, Lopez-Yurda, M.I., additional, Grijpink-Ongering, L., additional, Rawson, R., additional, Spillane, A.J., additional, Scolyer, R.A., additional, van de Wiel, B., additional, van Akkooi, A.C.J., additional, Long, G.V., additional, and Blank, C.U., additional

Published
2022
Full Text
View/download PDF

209. LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial

Author

Haanen, J.B.A.G., primary, Rohaan, M., additional, Borch, T.H., additional, van den Berg, J.H., additional, Met, Ö., additional, Foppen, M. Geukes, additional, Granhøj, J. Stoltenborg, additional, Nuijen, B., additional, Nijenhuis, C., additional, Beijnen, J.H., additional, Jedema, I., additional, van Zon, M., additional, Noringriis, I. Mansfield, additional, Kessels, R., additional, Wilgenhof, S., additional, van Thienen, H.V., additional, Lalezari, F., additional, van Akkooi, A.C.J., additional, Donia, M., additional, and Svane, I-M., additional

Published
2022
Full Text
View/download PDF

210. LBA43 Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: Interim efficacy and safety results of the randomized phase II INTRIM study

Author

Notohardjo, J.C.L., primary, Veenstra, S., additional, Koster, B.D., additional, Kandiah, V., additional, van der Velde, S., additional, Francken, A.B., additional, Gooiker, G.A., additional, van den Tol, M.P., additional, Bekkenk, M.W., additional, Hof, K.H. in 't, additional, Straver, M.E., additional, Molenkamp, B.G., additional, Vuylsteke, R.J.C.L.M., additional, Lissenberg-Witte, B.I., additional, Labots, M., additional, Chunduru, S.K., additional, van Akkooi, A.C.J., additional, Van Den Eertwegh, F., additional, and de Gruijl, T.D., additional

Published
2022
Full Text
View/download PDF

211. LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Author

Long, G.V., Blank, C.U., Amaria, R.N., Hieken, T.J., Sandhu, S.K., Barros, M.J., Mitchell, T.C.C., Eroglu, Z., Samoylenko, I.V., Rutkowski, P., Johnson, D., Pires da Silva, I., Perry, K.A., Tawbi, H.A., Block, M.S., Ascierto, P.A., Burton, E., van Akkooi, A.C.J., Scolyer, R.A., and Menzies, A.M.

Published
2024
Full Text
View/download PDF

213. 1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma

Author

Hoeijmakers, L., Dimitriadis, P., Cornelissen, S., Reijers, I., van de Wiel, B., Scolyer, R.A., Saw, R.P.M., Spillane, A.J., Broeks, A., Lopez-Yurda, M., Grijpink-Ongering, L., Hospers, G., Menzies, A.M., van Akkooi, A.C.J., Van Houdt, W., Long, G.V., and Blank, C.U.

Published
2024
Full Text
View/download PDF

214. 1076O Primary analysis of the EORTC 1208 Minitub trial: Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden

Author

van Akkooi, A.C.J., Massi, D., Kicinski, M., Brackley, P., Gruenhagen, D., Rastrelli, M., Signh, M., Peach, H., Peric, B., Caracò, C., Boecxstaens, V., Moncrieff, M., Marreaud, S.I., Louis, R., de Schaetzen, G., Koljenovic, S., van de Wiel, B., Mandalà, M., Cook, M., and Eggermont, A.M.M.

Published
2024
Full Text
View/download PDF

215. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

Author

Gauci, Marie-Léa, Aristei, Cynthia, Becker, Jurgen C, Blom, Astrid, Bataille, Veronique, Dreno, Brigitte, Del Marmol, Veronique, Forsea, Ana M, Fargnoli, Maria C, Grob, Jean-Jacques, Gomes, Fabio, Hauschild, Axel, Hoeller, Christoph, Harwood, Catherine, Kelleners-Smeets, Nicole, Kaufmann, Roland, Lallas, Aimilios, Malvehy, Josep, Moreno-Ramirez, David, Peris, Ketty, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iris, van Akkooi, Alexander C J, Lorigan, Paul, Garbe, Claus, Lebbé, Céleste, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Università degli Studi di Perugia = University of Perugia (UNIPG), German Cancer Consortium [Heidelberg] (DKTK), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Mount Vernon Cancer Centre [Northwood, UK] (MV2C), Mount Vernon Cancer Centre, Nantes Université (Nantes Univ), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université libre de Bruxelles (ULB), University Emergency Hospital [Bucharest], University of L'Aquila [Italy] (UNIVAQ), Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), University of Manchester [Manchester], University Hospital Schleswig-Holstein [Kiel, Germany], Medizinische Universität Wien = Medical University of Vienna, Queen Mary University of London (QMUL), Maastricht University [Maastricht], Frankfurt University Hospital, Aristotle University of Thessaloniki, University of Barcelona, Hospital Universitario Virgen Macarena [Séville], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), National and Kapodistrian University of Athens (NKUA), Coimbra Hospital and Universitary Centre [Coimbra, Portugal] (CHUC), Università degli studi di Trieste = University of Trieste, Antoni van Leeuwenhoek Hospital, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Roche, AbbVie, Genesis Pharma, J.C. Becker reports receiving speaker’s bureau honoraria from Amgen, Pfizer, Recordati and Sanofi, is a paid consultant/advisory board member/DSMB member for Almirall, Boehringer Ingelheim, InProTher, ICON, MerckSerono, Pfizer, 4SC, and Sanofi/Regeneron. His group receives research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis., Speaker’s bureau honoraria from Amgen, Pfizer, Recordati and Sanofi, paid consultant/advisory/DSMB board member for Almirall, Boehringer Ingelheim, ICON, InProTher, MerckSerono, Pfizer, 4SC, and Sanofi/Regeneron. Research grants from Bristol-Myers Squibb, Merck Serono, HTG, IQVIA, and Alcedis., Gauci, Marie-Léa, Aristei, Cynthia, Becker, Jurgen C, Blom, Astrid, Bataille, Veronique, Dreno, Brigitte, Del Marmol, Veronique, Forsea, Ana M, Fargnoli, Maria C, Grob, Jean-Jacque, Gomes, Fabio, Hauschild, Axel, Hoeller, Christoph, Harwood, Catherine, Kelleners-Smeets, Nicole, Kaufmann, Roland, Lallas, Aimilio, Malvehy, Josep, Moreno-Ramirez, David, Peris, Ketty, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J, Vieira, Ricardo, Zalaudek, Iri, van Akkooi, Alexander C J, Lorigan, Paul, Garbe, Clau, and Lebbé, Céleste

Subjects
Male, Cancer Research, Skin Neoplasms, Consensus, Consensu, HIV Infections/complications, HIV Infections, [SDV.CAN]Life Sciences [q-bio]/Cancer, Guideline, Guidelines, Sentinel Lymph Node Biopsy/adverse effects, Merkel Cell/diagnosis, Humans, HIV Infection, Skin Neoplasms/diagnosis, Neoplasm Staging, MCC, Merkel cell, Manchester Cancer Research Centre, Sentinel Lymph Node Biopsy, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Carcinoma, Merkel Cell, EDF, Oncology, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human
Abstract

International audience; Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Five-year overall survival rates range between 48% and 63%. Two subsets of MCC have been characterised with distinct molecular pathogenetic pathways: ultraviolet-induced MCC versus virus-positive MCC, which carries a better prognosis. In both subtypes, there are alterations in the retinoblastoma protein and p53 gene structure and function. MCC typically manifests as a red nodule or plaque with fast growth, most commonly on sun exposed areas. Histopathology (small-cell neuroendocrine appearance) and immunohistochemistry (CK20 positivity and TTF-1 negativity) confirm the diagnosis. The current staging systems are the American Joint Committee on Cancer/Union for international Cancer control 8th edition. Baseline whole body imaging is encouraged to rule out regional and distant metastasis. For localised MCC, first-line treatment is surgical excision with postoperative margin assessment followed by adjuvant radiation therapy (RT). Sentinel lymph node biopsy is recommended in all patients with MCC without clinically detectable lymph nodes or distant metastasis. Adjuvant RT alone, eventually combined with complete lymph nodes dissection is proposed in case of micrometastatic nodal involvement. In case of macroscopic nodal involvement, the standard of care is complete lymph nodes dissection potentially followed by post-operative RT. Immunotherapy with anti-PD-(L)1 antibodies should be offered as first-line systemic treatment in advanced MCC. Chemotherapy can be used when patients fail to respond or are intolerant for anti-PD-(L)1 immunotherapy or clinical trials.

Published
2022

216. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes

Author

Schouwenburg, Maartje G., Jochems, Anouk, Leeneman, Brenda, Franken, Margreet G., van den Eertwegh, Alfons J.M., Haanen, John B.A.G., van Zeijl, Michiel C.T., Aarts, Maureen J., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Blokx, Willeke A.M., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, Koornstra, Rutger H., Kruit, Wim H., Louwman, Marieke W.J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P.M., ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W.J.M., and van der Hoeven, Jacobus J.M.

Published
2018
Full Text
View/download PDF

220. 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Author

Reijers, Dimitriadis, P., Traets, J.J., Saw, R., Versluis, J.M., Pennington, T., Kapiteijn, E., Van der Veldt, A.A.M., Suijkerbuijk, K., Hospers, G., Van Houdt, W., Broeks, A., Cornelissen, S., Spillane, A., Scolyer, R., van de Wiel, B., Menzies, A.M., van Akkooi, A.C.J., Long, G.V., and Blank, C.U.

Published
2022
Full Text
View/download PDF

221. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients

Author

Emma H.A. Stahlie, Evalyn E.A.P. Mulder, Sophie Reijers, Sara Balduzzi, Charlotte L. Zuur, Willem M.C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W.J.M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C.J. van Akkooi, Surgery, and Medical Oncology

Subjects
Oncolytic Virotherapy, Biological Products, T-VEC, Skin Neoplasms, Oncology, Humans, Metastatic, Herpesvirus 1, Human, Hematology, Immunotherapy, Melanoma
Abstract

Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review and meta-analysis was to investigate the efficacy and safety of T-VEC. Of 341 publications that were identified, eight studies with a total of 642 patients were included. In patients with stage IIIB-IVM1a, the pooled complete- and overall response rate (CRR and ORR) were 41% and 64%, respectively. In patients with stage IIIB-IVM1c, the pooled CRR and ORR were 30% and 44%, respectively. In patients with stage IVM1b and IVM1c, the pooled CRR and ORR were 4% and 9%, respectively. Adverse events (AEs) were seen in 41–100% of all patients and 0–11% of AEs were severe. In conclusion, single agent T-VEC achieves the highest response rates in patients with early metastatic melanoma and is well-tolerated with generally only mild toxicities.

Published
2022

223. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Author

Becker, Jürgen C, Ugurel, Selma, Leiter, Ulrike, Meier, Friedegund, Gutzmer, Ralf, Haferkamp, Sebastian, Zimmer, Lisa, Livingstone, Elisabeth, Eigentler, Thomas K, Hauschild, Axel, Kiecker, Felix, Hassel, Jessica C, Mohr, Peter, Fluck, Michael, Thomas, Ioannis, Garzarolli, Marlene, Grimmelmann, Imke, Drexler, Konstantin, Spillner, Alexandra N, Eckhardt, Sebastian, Schadendorf, Dirk, van Akkooi, Alexander, van Houdt, Winan, Wilhelm, Tabea, Farmer, Kimberley, Ulrich, Claas, Gambichler, Thilo, Bluhm, Leonie, Schinagl, Heidemarie, Kellner, Ivonne, Herbst, Rudolf, Meiß, Frank, Rafei-Shamsabadi, David, Sell, Sabine, Kaatz, Martin, Wulfken, Lena, Hartmann, Martin, Kähler, Katharina, Ziemer, Mirjana, Simon, Jan, Terheyden, Patrick, Thaci, Diamant, Loquai, Carmen, Mitzel-Rink, Heidrun, Grabbe, Stephan, Stege, Henner, Gaiser, Maria, Utikal, Jochen, Berking, Carola, Heinzerling, Lucie, Schlaak, Max, Tomsitz, Dirk, Dyballa, Jörg, Magnolo, Nina, Weishaupt, Carsten, Berneburg, Mark, Garbe, Claus, Flatz, Lukas, Gesierich, Anja, and Schilling, Bastian

Abstract

Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC. We aimed to assess efficacy and safety of adjuvant immune checkpoint inhibition in completely resected MCC (ie, a setting without an established systemic standard-of-care treatment).

Published
2023
Full Text
View/download PDF

226. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

Author

Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, and Alexander M. Menzies

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Ipilimumab, Metastasis, Neoplasms, Multiple Primary, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Melanoma, Lymph node, Neoadjuvant therapy, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Middle Aged, medicine.disease, Neoadjuvant Therapy, Survival Rate, Clinical trial, Nivolumab, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Lymphadenectomy, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug
Abstract

Background Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impressive relapse-free survival in patients with nodal macroscopic stage III melanoma. Whether primary site melanoma and in-transit metastases respond similarly to lymph node metastases with neoadjuvant immunotherapy is largely unknown. Such data would clarify whether surgical excision of these melanoma lesions should be performed before neoadjuvant therapy or whether it could be deferred and performed in conjunction with lymphadenectomy following neoadjuvant immunotherapy. Patients Patients with synchronous clinical stage III melanoma were identified from the OpACIN, OpACIN-neo and PRADO neoadjuvant trials, where all patients were treated with ipilimumab plus nivolumab. An additional case treated outside those clinical trials was included. Results Seven patients were identified; six patients had a concordant response in primary site melanoma lesions or in-transit metastasis and the lymph node metastases. One patient had concordant progression in both the primary and nodal tumour lesions and developed stage IV disease during neoadjuvant treatment, and thus, no resection was performed. Conclusion Pathologic response following neoadjuvant ipilimumab plus nivolumab in primary site melanoma lesions or in-transit metastasis is concordant with a response in the lymph node metastases, indicating that there may be no need to perform upfront surgery to these melanoma lesions prior to neoadjuvant treatment.

Published
2021

227. Current management of melanoma patients with nodal metastases

Author

Adrienne B. Shannon, Kevin B. Kim, Lin Wang, Dale Han, Giorgos C. Karakousis, Douglas S. Reintgen, Richard J. Straker, and Alexander C.J. van Akkooi

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Completion lymph node dissection, medicine.medical_treatment, Sentinel lymph node, Neoadjuvant systemic therapy, Review, Adjuvant systemic therapy, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Surgical oncology, Internal medicine, Biopsy, medicine, Humans, Lymph node, Melanoma, medicine.diagnostic_test, business.industry, Sentinel Lymph Node Biopsy, Neoplasms, Second Primary, General Medicine, medicine.disease, Prognosis, Immune checkpoint inhibitor and targeted therapy, Clinical trial, Dissection, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Lymph Node Excision, Sentinel lymph node metastasis, business
Abstract

The management of melanoma patients with nodal metastases has undergone dramatic changes over the last decade. In the past, the standard of care for patients with a positive sentinel lymph node biopsy (SLNB) was a completion lymph node dissection (CLND), while patients with palpable macroscopic nodal disease underwent a therapeutic lymphadenectomy in cases with no evidence of systemic spread. However, studies have shown that SLN metastases present as a spectrum of disease, with certain SLN-based factors being prognostic of and correlated with outcomes. Furthermore, the results of key clinical trials demonstrate that CLND provides no survival benefit over nodal observation in positive SLN patients, while other clinical trials have shown that adjuvant immune checkpoint inhibitor therapy or targeted therapy after CLND is associated with a recurrence-free survival benefit. Given the efficacy of these systemic therapies in the adjuvant setting, these agents are now being evaluated and utilized as neoadjuvant treatments in patients with regionally-localized or resectable metastatic melanoma. Multiple options now exist to treat melanoma patients with nodal disease, and determining the best treatment course for a particular case requires an in-depth knowledge of current data and an informed discussion with the patient. This review will provide an overview of the various options for treating melanoma patients with nodal metastases and will discuss the data that supported the development of these treatment options.

Published
2021

228. The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB

Author

A.C.J. van Akkooi, B.A. van de Wiel, B. van der Hiel, Yvonne Schrage, Michel W.J.M. Wouters, Emma H. A. Stahlie, Annemarie Bruining, and W.J. van Houdt

Subjects
PET-CT, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Melanoma, Sentinel lymph node, General Medicine, medicine.disease, 03 medical and health sciences, Dissection, 0302 clinical medicine, medicine.anatomical_structure, Fine-needle aspiration, Oncology, 030220 oncology & carcinogenesis, Biopsy, medicine, Adjuvant therapy, Surgery, 030212 general & internal medicine, Radiology, business, Lymph node
Abstract

Background Stage IIB/IIC (8th AJCC) melanoma patients are known to have high-risk primary tumors, however they follow the same routine to sentinel lymph node biopsy (SLNB) as more low risk tumors. Guidelines are not conclusive regarding the use of preoperative imaging for these patients. The aim of this pilot study was to assess the value of ultrasound (US) and 18F-FDG PET/CT prior to lymphoscintigraphy (LSG) and SLNB for stage IIB/C melanoma patients. Methods From 2019-04 till 2020–01, all stage IIB/C melanoma patients underwent US of the regional lymph nodes and whole body 18F-FDG PET/CT before their planned LSG and SLNB. Suspected metastases were confirmed with fine needle aspiration (FNA), prior to surgery. Results In total 23 patients were screened: six had metastases detected by imaging, two by US, one by 18F-FDG PET/CT and three were detected by both imaging modalities. All metastases were nodal and therefore treatment was altered to lymph node dissection and all but one also received adjuvant therapy. Eight (47%) of the 17 patients without macroscopic disease, still had a positive SN. Sensitivity, specificity and false negative rate for US and 18F-FDG PET/CT were 36%, 89%, 64% and 29%, 100% and 71%, respectively. Conclusion Preoperative negative imaging does not exclude the presence of SN metastases, therefore SLNB cannot be foregone. However, US detected metastases in 22% of patients, altering their treatment, which suggests it is effective in the work-up of stage IIB/C melanoma. Staging with 18F-FDG PET/CT is not of added value prior to LSG and SLNB and should therefore not be used.

Published
2021

229. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

Author

D. Verver, Astrid A M van der Veldt, Jan Willem B. de Groot, Maureen J.B. Aarts, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Karijn P M Suijkerbuijk, Franchette W P J van den Berkmortel, Gerard Vreugdenhil, Djura Piersma, Marye J Boers-Sonderen, Ellen Kapiteijn, Albert J. ten Tije, Dirk J. Grünhagen, Cornelis Verhoef, Geke A. P. Hospers, Rozemarijn S. van Rijn, Alexander C.J. van Akkooi, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Surgery, Medical Oncology, and Radiology & Nuclear Medicine

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, medicine.medical_treatment, Immunology, Antineoplastic Agents, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Targeted therapy, 03 medical and health sciences, Known primary, 0302 clinical medicine, Interquartile range, Internal medicine, Novel therapy, Immunology and Allergy, Medicine, Humans, Stage IIIC, 030212 general & internal medicine, Molecular Targeted Therapy, Melanoma, Immune Checkpoint Inhibitors, Aged, Performance status, business.industry, Proportional hazards model, Unknown primary, Hazard ratio, Middle Aged, medicine.disease, Confidence interval, 030220 oncology & carcinogenesis, Neoplasms, Unknown Primary, Original Article, Female, business
Abstract

Melanoma of unknown primary (MUP) is considered different from melanoma of known primary (MKP), and it is unclear whether these patients benefit equally from novel therapies. In the current study, characteristics and overall survival (OS) of patients with advanced and metastatic MUP and MKP were compared in the era of novel therapy. Patients were selected from the prospective nation-wide Dutch Melanoma Treatment Registry (DMTR). The following criteria were applied: diagnosis of stage IIIc unresectable or IV cutaneous MKP (cMKP) or MUP between July 2012 and July 2017 and treatment with immune checkpoint inhibition and/or targeted therapy. OS was estimated using the Kaplan–Meier method. The stratified multivariable Cox regression model was used for adjusted analysis. A total of 2706 patients were eligible including 2321 (85.8%) patients with cMKP and 385 (14.2%) with MUP. In comparative analysis, MUP patients more often presented with advanced and metastatic disease at primary diagnosis with poorer performance status, higher LDH, and central nervous system metastases. In crude analysis, median OS of cMKP or MUP patients was 12 months (interquartile range [IQR] 5 – 44) and 14 months (IQR 5 – not reached), respectively (P = 0.278). In adjusted analysis, OS in MUP patients was superior (hazard rate 0.70, 95% confidence interval 0.58–0.85; P

Published
2021

231. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

Author

Eroglu, Zeynep, primary, Broman, Kristy K, additional, Thompson, John F, additional, Nijhuis, Amanda, additional, Hieken, Tina J, additional, Kottschade, Lisa, additional, Farma, Jeffrey M, additional, Hotz, Meghan, additional, Deneve, Jeremiah, additional, Fleming, Martin, additional, Bartlett, Edmund K, additional, Sharma, Avinash, additional, Dossett, Lesly, additional, Hughes, Tasha, additional, Gyorki, David E, additional, Downs, Jennifer, additional, Karakousis, Giorgos, additional, Song, Yun, additional, Lee, Ann, additional, Berman, Russell S, additional, van Akkooi, Alexander, additional, Stahlie, Emma, additional, Han, Dale, additional, Vetto, John, additional, Beasley, Georgia, additional, Farrow, Norma E, additional, Hui, Jane Yuet Ching, additional, Moncrieff, Marc, additional, Nobes, Jenny, additional, Baecher, Kirsten, additional, Perez, Matthew, additional, Lowe, Michael, additional, Ollila, David W, additional, Collichio, Frances A, additional, Bagge, Roger Olofsson, additional, Mattsson, Jan, additional, Kroon, Hidde M, additional, Chai, Harvey, additional, Teras, Jyri, additional, Sun, James, additional, Carr, Michael J, additional, Tandon, Ankita, additional, Babacan, Nalan Akgul, additional, Kim, Younchul, additional, Naqvi, Mahrukh, additional, Zager, Jonathan, additional, and Khushalani, Nikhil I, additional

Published
2022
Full Text
View/download PDF

232. ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma—An International Multi-institutional Collaboration

Author

Walker, Richard J. B., primary, Look Hong, Nicole J., additional, Moncrieff, Marc, additional, van Akkooi, Alexander C. J., additional, Jost, Evan, additional, Nessim, Carolyn, additional, van Houdt, Winan J., additional, Stahlie, Emma H. A., additional, Seo, Chanhee, additional, Quan, May Lynn, additional, McKinnon, J. Gregory, additional, Wright, Frances C., additional, and Mavros, Michail N., additional

Published
2022
Full Text
View/download PDF

233. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study

Author

Holmberg, Carl-Jacob, primary, Ny, Lars, additional, Hieken, Tina J., additional, Block, Matthew S., additional, Carr, Michael J., additional, Sondak, Vernon K., additional, Örtenwall, Christoffer, additional, Katsarelias, Dimitrios, additional, Dimitriou, Florentia, additional, Menzies, Alexander M., additional, Saw, Robyn PM., additional, Rogiers, Aljosja, additional, Straker, Richard J., additional, Karakousis, Giorgos, additional, Applewaite, Rona, additional, Pallan, Lalit, additional, Han, Dale, additional, Vetto, John T., additional, Gyorki, David E., additional, Tie, Emilia Nan, additional, Vitale, Maria Grazia, additional, Ascierto, Paulo A., additional, Dummer, Reinhard, additional, Cohen, Jade, additional, Hui, Jane YC., additional, Schachter, Jacob, additional, Asher, Nethanel, additional, Helgadottir, H., additional, Chai, Harvey, additional, Kroon, Hidde, additional, Coventry, Brendon, additional, Rothermel, Luke D., additional, Sun, James, additional, Carlino, Matteo S., additional, Duncan, Zoey, additional, Broman, Kristy, additional, Weber, Jeffrey, additional, Lee, Ann Y., additional, Berman, Russell S., additional, Teras, Jüri, additional, Ollila, David W., additional, Long, Georgina V., additional, Zager, Jonathan S., additional, van Akkooi, Alexander, additional, and Olofsson Bagge, Roger, additional

Published
2022
Full Text
View/download PDF

234. Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis

Author

Stahlie, Emma H.A., primary, Mulder, Evalyn E.A.P., additional, Reijers, Sophie, additional, Balduzzi, Sara, additional, Zuur, Charlotte L., additional, Klop, Willem M.C., additional, van der Hiel, Bernies, additional, Van de Wiel, Bart A., additional, Wouters, Michel W.J.M., additional, Schrage, Yvonne M., additional, van Houdt, Winan J., additional, Grunhagen, Dirk J., additional, and van Akkooi, Alexander C.J., additional

Published
2022
Full Text
View/download PDF

235. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Author

Garbe, Claus, primary, Amaral, Teresa, additional, Peris, Ketty, additional, Hauschild, Axel, additional, Arenberger, Petr, additional, Basset-Seguin, Nicole, additional, Bastholt, Lars, additional, Bataille, Veronique, additional, del Marmol, Veronique, additional, Dréno, Brigitte, additional, Fargnoli, Maria C., additional, Forsea, Ana-Maria, additional, Grob, Jean-Jacques, additional, Hoeller, Christoph, additional, Kaufmann, Roland, additional, Kelleners-Smeets, Nicole, additional, Lallas, Aimilios, additional, Lebbé, Celeste, additional, Lytvynenko, Bodhan, additional, Malvehy, Josep, additional, Moreno-Ramirez, David, additional, Nathan, Paul, additional, Pellacani, Giovanni, additional, Saiag, Philippe, additional, Stratigos, Alexander J., additional, Van Akkooi, Alexander C.J., additional, Vieira, Ricardo, additional, Zalaudek, Iris, additional, and Lorigan, Paul, additional

Published
2022
Full Text
View/download PDF

236. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration

Author

Walker, Richard J. B., primary, Look Hong, Nicole J., additional, Moncrieff, Marc, additional, van Akkooi, Alexander C. J., additional, Jost, Evan, additional, Nessim, Carolyn, additional, van Houdt, Winan J., additional, Stahlie, Emma H. A., additional, Seo, Chanhee, additional, Quan, May Lynn, additional, McKinnon, J. Gregory, additional, Wright, Frances C., additional, and Mavros, Michail N., additional

Published
2022
Full Text
View/download PDF

238. Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

Author

Blank, Christian U., primary, Reijers, Irene L.M., additional, Saw, Robyn P.M., additional, Versluis, Judith M., additional, Pennington, Thomas, additional, Kapiteijn, Ellen, additional, Van Der Veldt, Astrid Aplonia Maria, additional, Suijkerbuijk, Karijn, additional, Hospers, Geke, additional, van Houdt, Winan J., additional, Klop, W. Martin. C., additional, Sikorska, Karolina, additional, Van Der Hage, Jos A., additional, Grunhagen, Dirk J., additional, Colebatch, Andrew J, additional, Spillane, Andrew John, additional, van de Wiel, Bart A., additional, Menzies, Alexander M., additional, Van Akkooi, Alexander Christopher Jonathan, additional, and Long, Georgina V., additional

Published
2022
Full Text
View/download PDF

239. Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.

Author

Versluis, Judith M., primary, Sikorska, Karolina, additional, Rozeman, Elisa A., additional, Menzies, Alexander M., additional, Eriksson, Hanna, additional, Klop, W. Martin. C., additional, Saw, Robyn P.M., additional, van de Wiel, Bart A., additional, Scolyer, Richard A., additional, van Thienen, Johannes V., additional, Mallo, Henk, additional, Gonzalez, Maria, additional, Torres Acosta, Alex, additional, Grijpink-Ongering, Lindsay G., additional, van der Wal, Anja, additional, Haanen, John B. A. G., additional, Van Akkooi, Alexander Christopher Jonathan, additional, Long, Georgina V., additional, and Blank, Christian U., additional

Published
2022
Full Text
View/download PDF

241. The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.

Author

Lucas, Minke W., primary, Lijnsvelt, Judith, additional, Pulleman, Saskia, additional, Scolyer, Richard A., additional, Menzies, Alexander M., additional, Van Akkooi, Alexander Christopher Jonathan, additional, van Houdt, Winan J., additional, Shannon, Kerwin Frank, additional, Pennington, Thomas, additional, Suijkerbuijk, Karijn, additional, Kapiteijn, Ellen, additional, Van Der Veldt, Astrid Aplonia Maria, additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, Gonzalez, Maria, additional, Zuur, Charlotte L., additional, Klop, W. Martin. C., additional, Long, Georgina V., additional, and Blank, Christian U., additional

Published
2022
Full Text
View/download PDF

242. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

Reijers, Irene L. M., primary, Menzies, Alexander M., additional, van Akkooi, Alexander C. J., additional, Versluis, Judith M., additional, van den Heuvel, Noëlle M. J., additional, Saw, Robyn P. M., additional, Pennington, Thomas E., additional, Kapiteijn, Ellen, additional, van der Veldt, Astrid A. M., additional, Suijkerbuijk, Karijn P. M., additional, Hospers, Geke A. P., additional, Rozeman, Elisa A., additional, Klop, Willem M. C., additional, van Houdt, Winan J., additional, Sikorska, Karolina, additional, van der Hage, Jos A., additional, Grünhagen, Dirk J., additional, Wouters, Michel W., additional, Witkamp, Arjen J., additional, Zuur, Charlotte L., additional, Lijnsvelt, Judith M., additional, Torres Acosta, Alejandro, additional, Grijpink-Ongering, Lindsay G., additional, Gonzalez, Maria, additional, Jóźwiak, Katarzyna, additional, Bierman, Carolien, additional, Shannon, Kerwin F., additional, Ch’ng, Sydney, additional, Colebatch, Andrew J., additional, Spillane, Andrew J., additional, Haanen, John B. A. G., additional, Rawson, Robert V., additional, van de Wiel, Bart A., additional, van de Poll-Franse, Lonneke V., additional, Scolyer, Richard A., additional, Boekhout, Annelies H., additional, Long, Georgina V., additional, and Blank, Christian U., additional

Published
2022
Full Text
View/download PDF

245. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials

Author

James Larkin, Jeffrey S. Weber, F. Stephen Hodi, Paolo A. Ascierto, Roger Olofsson Bagge, Georgina V. Long, Alexander C.J. van Akkooi, Jacob Schachter, Caroline Robert, and Lars Ny

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Ipilimumab, Dermatology, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Clinical endpoint, Humans, Medicine, Neoplasm Metastasis, Stage (cooking), Melanoma, Randomized Controlled Trials as Topic, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Nivolumab, business, medicine.drug
Abstract

Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases. The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease. However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect. This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival. The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified. The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis. The primary endpoint was complete response rate. Seven trials that included stage III patients, and with accessible datasets, were identified. There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms. Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking. We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required.

Published
2021

246. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Author

Christian U. Blank, Rodabe N. Amaria, Jennifer A. Wargo, Bart A. van de Wiel, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Alexander C. Huang, Xiaowei Xu, Richard A. Scolyer, Tara C. Mitchell, Giorgos C. Karakousis, Alexander C.J. van Akkooi, Michael A. Davies, Andrew J. Spillane, Elisa A. Rozeman, Alexander M. Menzies, Robyn P. M. Saw, Michael T. Tetzlaff, Ahmad A. Tarhini, Thomas E. Pennington, Elizabeth M. Burton, Paolo A. Ascierto, and Serigne Lo

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Surrogate endpoint, Melanoma, medicine.medical_treatment, Ipilimumab, General Medicine, Immunotherapy, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Targeted therapy, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, Nivolumab, business, Neoadjuvant therapy, medicine.drug
Abstract

The association among pathological response, recurrence-free survival (RFS) and overall survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we pooled data from six clinical trials of anti-PD-1-based immunotherapy or BRAF/MEK targeted therapy. In total, 192 patients were included; 141 received immunotherapy (104, combination of ipilimumab and nivolumab; 37, anti-PD-1 monotherapy), and 51 received targeted therapy. A pathological complete response (pCR) occurred in 40% of patients: 47% with targeted therapy and 33% with immunotherapy (43% combination and 20% monotherapy). pCR correlated with improved RFS (pCR 2-year 89% versus no pCR 50%, P

Published
2021

247. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Author

A.C.J. van Akkooi, Judith M. Versluis, Christian U. Blank, Charlotte L. Zuur, Elisa A. Rozeman, Willem M.C. Klop, Esmée P. Hoefsmit, Lindsay G Grijpink-Ongering, María Jesús González González, Sandra Adriaansz, Robyn P. M. Saw, Sydney Ch'ng, Sten Cornelissen, J Stretch, Annegien Broeks, Ton N. Schumacher, A A Torres Acosta, Hanna Eriksson, Ron M. Kerkhoven, B.A. van de Wiel, Petros Dimitriadis, Richard A. Scolyer, Oscar Krijgsman, Daniel S. Peeper, J.B.A.G. Haanen, Omgo E. Nieweg, Karolina Sikorska, Kerwin F. Shannon, Georgina V. Long, W.J. van Houdt, A.M. Menzies, H. Mallo, Irene L.M. Reijers, and Andrew J. Spillane

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Melanoma, Phases of clinical research, Ipilimumab, General Medicine, medicine.disease, General Biochemistry, Genetics and Molecular Biology, law.invention, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, medicine, Adjuvant therapy, Biomarker (medicine), Nivolumab, business, medicine.drug
Abstract

Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2. While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response (n = 7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo (n = 86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P

Published
2021

249. 797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm

Author

I.L.M. Reijers, A.M. Menzies, J.M. Versluis, P. Dimitriadis, M. Wouters, R.P.M. Saw, M.C. Klop, T.E. Pennington, W. Van Houdt, L.J.W. Bosch, S. Cornelissen, M.I. Lopez-Yurda, L. Grijpink-Ongering, R. Rawson, A.J. Spillane, R.A. Scolyer, B. van de Wiel, A.C.J. van Akkooi, G.V. Long, and C.U. Blank

Subjects
Oncology, Hematology
Published
2022

250. ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration

Author

Richard J. B. Walker, Nicole J. Look Hong, Marc Moncrieff, Alexander C. J. van Akkooi, Evan Jost, Carolyn Nessim, Winan J. van Houdt, Emma H. A. Stahlie, Chanhee Seo, May Lynn Quan, J. Gregory McKinnon, Frances C. Wright, and Michail N. Mavros

Subjects
Oncology, Lymphatic Metastasis, Humans, Surgery, Sentinel Lymph Node, Melanoma
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results